Anti-colorectal cancer effects of IRX4 and sensitivity studies to oxaliplatin
These findings suggest that IRX4 may be a prognostic biomarker and therapeutic target in CRC. Moreover, IRX4 might regulate CRC progression and chemosensitivity by inhibiting the NF-κB /EGFR pathway, suggesting its potential as a therapeutic target to improve chemotherapeutic efficacy in CRC.
Authors
- Yabin Liu
- Mei juan Jia
- Binghui Li
- Kong Peng
- Dexian Kong
- Jiaxu Fan
- Shuang Liu
- Jian Zhao
- Bingqian Heng
Institutions
- Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- First Hospital of Shijiazhuang (CN)
- Bethune International Peace Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-21
- DOI
- https://doi.org/10.3389/fimmu.2025.1581244
- Primary Topic
- Cancer-related gene regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00